Participated · Equity · Jul 2026

Xaga Surgical’s core product is a proprietary prostate biopsy device with a redesigned needle architecture that clinical studies indicate can reduce bacterial transmission by up to 96% and provide a more stable trajectory during tissue sampling. The company received FDA 510(k) clearance for the device and it is already being used by clinicians at institutions such as the Penn State College of Medicine. Xaga was founded by urologist Dr. Andreas Forsvall, who developed the technology based on clinical shortcomings he observed. Xaga reports that traditional biopsy needles contribute to complications in roughly 3% of procedures globally, and its device aims to lower those risks while improving diagnostic accuracy. The company recently raised 17 million SEK (≈€1.6M) to scale manufacturing and commercial operations in the U.S., prepare for CE marking in Europe, and pursue a broader portfolio of infection-prevention technologies for needle-based procedures.

Participated · Equity · Oct 2025

Founded in 2020 in Sweden, Saveggy offers a two-ingredient, edible coating made from rapeseed and oat oils that shields produce and prolongs freshness, eliminating the need for single-use polyethylene wraps. The technology is currently being piloted with retailer ICA and grower Odlarna.se, covering about 250,000 cucumbers across 700 Swedish stores. By targeting produce like cucumbers, which account for more than 3,000 tonnes of plastic packaging annually in the EU, the company addresses both food waste and plastic pollution. Early research and development were carried out in collaboration with Lund University, Aarhus University, the European Institute of Technology (EIT) and other value-chain stakeholders. To date, Saveggy has secured €2.5 million from investors including Fåhraeus Startup and Growth, LRF Ventures, Unconventional Ventures, Almi Greentech and Smile Inject Capital. The startup plans to expand its coating to additional produce categories and new geographic markets following the trial. Management is preparing for a larger funding round targeted for 2026 to scale commercial production and distribution.